Oculis Holding AG (NASDAQ:OCS) Receives Average Rating of “Moderate Buy” from Analysts

Oculis Holding AG (NASDAQ:OCS) has been given an average recommendation of “Moderate Buy” by the ten analysts that are covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation and nine have issued a buy recommendation on the company. The average 12 month target price among analysts that have covered the stock in the last year is $39.4444.

A number of brokerages recently issued reports on OCS. Robert W. Baird decreased their price target on shares of Oculis from $49.00 to $38.00 and set an “outperform” rating for the company in a research note on Monday, June 1st. HC Wainwright boosted their target price on shares of Oculis from $26.00 to $39.00 and gave the stock a “buy” rating in a research note on Friday. Wall Street Zen raised Oculis from a “strong sell” rating to a “sell” rating in a report on Saturday, August 8th. Guggenheim cut their target price on Oculis from $75.00 to $45.00 and set a “buy” rating on the stock in a research report on Monday, June 1st. Finally, JPMorgan Chase & Co. lowered their price target on Oculis from $23.00 to $20.00 and set an “overweight” rating for the company in a report on Friday, August 14th.

Institutional Trading of Oculis

Several institutional investors have recently modified their holdings of the stock. Braidwell LP purchased a new position in shares of Oculis in the 2nd quarter valued at $11,570,000. NEXTBio Capital Management LP purchased a new stake in Oculis in the fourth quarter valued at $2,991,000. Folketrygdfondet purchased a new stake in Oculis in the fourth quarter valued at $3,651,000. Simplify Asset Management Inc. acquired a new position in Oculis in the fourth quarter valued at $1,972,000. Finally, Propel Bio Management LLC acquired a new position in Oculis in the fourth quarter valued at $3,452,000. Hedge funds and other institutional investors own 22.30% of the company’s stock.

Oculis Stock Up 0.7%

Shares of NASDAQ:OCS opened at $9.98 on Friday. The firm has a market capitalization of $578.64 million, a PE ratio of -5.74 and a beta of 0.52. Oculis has a 1 year low of $9.65 and a 1 year high of $34.47. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.35 and a quick ratio of 8.35. The firm’s 50-day moving average is $12.10 and its two-hundred day moving average is $19.01.

Oculis (NASDAQ:OCS) last posted its quarterly earnings data on Tuesday, June 30th. The company reported ($0.20) EPS for the quarter. The business had revenue of $0.38 million during the quarter. Oculis had a negative net margin of 6,777.18% and a negative return on equity of 42.61%. Analysts predict that Oculis will post -2.01 EPS for the current year.

Oculis Company Profile

Oculis is a clinical-stage biopharmaceutical company focused on developing ophthalmic therapies for eye diseases and vision loss. The company uses proprietary drug-delivery technologies designed to improve the delivery of treatments to specific tissues in the eye, with the goal of offering effective and convenient alternatives to injections or other invasive procedures.

Oculis’ pipeline includes OCS-01, a topical eye-drop formulation of dexamethasone being developed for diabetic macular edema and inflammation following ocular surgery.